AstraZeneca leads the way for PARP-inhibitor ovarian cancer treatments.
By Dominique Fontanilla, Senior Analyst
12 September 2014
I joined Datamonitor Healthcare’s disease team in 2014 having previously worked as a biochemistry postdoctoral fellow ...
Read full bio
Pharma giant AstraZeneca is currently leading the way in the development of a new PARP (poly ADP-ribose polymerase) inhibitor for the treatment of ovarian cancer, according to our recent analysis. Our pipeline research (click here to view more) has identified three PARP inhibitors, Lynparza (AstraZeneca), niraparib (Tesaro) and rucaparib (Clovis Oncology), which induce cell death in mutated [BRCA-deficient] cancer cells.
Dr. Dominique Fontanilla, analyst at Datamonitor Healthcare said: “PARP inhibitors seem to have beneficial effects on tumors in women with BRCA mutations in clinical trials, and if AstraZeneca’s Lynparza were to be approved for use as a monotherapy, it would no doubt address an unmet need in the market.
“However, more research is needed to understand exactly which ovarian cancer patients will most likely benefit from these therapies.”
By the end of 2021, the number of ovarian cancer cases in the US alone will have increased by about 17% to roughly 30,400, meaning that US patients will still account for approximately 40% of all ovarian cancer cases in the seven major markets.
Posted in Oncology.